OTC · PLLWF
Polarean Imaging plc
$0.01$0.00 (0.0%)
Polarean Imaging plc’s quoted price sits in the upper half of its reported 52-week range, 1.49% below the high.
Loading market information…
OTC · TLIS · USD
Stock price, earnings
Quote as of Apr 1, 2026, 01:30 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Talis Biomedical Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Talis Biomedical Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Talis Biomedical Corporation specializes in molecular diagnostics, focusing on the creation of its Talis One system. This system is being developed to address and resolve existing limitations within current point-of-care diagnostic testing technologies for infectious diseases. The company currently provides the Talis One COVID-19 Test System, which is specifically designed for the detection of SARS-CoV-2, the virus responsible for COVID-19. Beyond this, Talis is also developing a range of Talis One assay kits to target respiratory infections, infections related to women's health, and sexually transmitted infections. Its pipeline further includes other diagnostic tests for various respiratory pathogens, such as a panel test capable of identifying influenza A, influenza B, and respiratory syncytial virus. Established in 2013, Talis Biomedical Corporation is headquartered in Menlo Park, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 12:10 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $137.00K-45.2% vs estimate |
| Q4 2022 | Mar 22, 2023 | -$14.99-31.61% vs estimate | $107.00K-86.63% vs estimate |
|---|
| Q3 2022 | Nov 3, 2022 | -$14.69-32.46% vs estimate | $730.00K+102.78% vs estimate |
|---|
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.01$0.00 (0.0%)
Polarean Imaging plc’s quoted price sits in the upper half of its reported 52-week range, 1.49% below the high.
$0.10$0.00 (0.0%)
Delota Corp.: Healthcare · Medical - Pharmaceuticals.
$0.01$0.00 (0.0%)
Reliq Health Technologies Inc.: Healthcare · Medical - Healthcare Information Services.
$0.00+$0.00 (+33.33%)
Lifeline Biotechnologies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 63.64% below the high.
CA$0.03CA$0.00 (0.0%)
Therma Bright Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.73% below the high.
$0.01$0.00 (0.0%)
Nu-Med Plus, Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.0% below the high.
$0.00$0.00 (0.0%)
Resilient Healthcare Corp’s quoted price sits in the lower half of its reported 52-week range, 92.98% below the high.
$0.00$0.00 (0.0%)
IR-Med Inc.’s quoted price sits in the lower half of its reported 52-week range, 95.8% below the high.
